Athira Pharma (NASDAQ:LONA) Stock Price Down 34.9% – Should You Sell?Defense World · Sep 27, 2026
LeonaBio to Participate in Cantor Global Healthcare Conference 2026GlobeNewsWire · Sep 3, 2026
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast CancerGlobeNewsWire · Aug 12, 2026LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$1.39 | -$0.80 | Beat |
| May 7, 2026 | -$2.28 | -$1.73 | Beat |
| Mar 26, 2026 | -$1.35 | -$18.92 | Miss |
| Nov 6, 2025 | -$1.06 | -$1.68 | Miss |
| Aug 7, 2025 | -$1.80 | -$1.80 | Beat |
| May 9, 2025 | -$2.00 | -$2.30 | Miss |